GSK Plc - ADR
GSK
Market Cap$84.56B
Close$
Earnings Call Q4 2023
January 31, 2024 - AI Summary
GSK reported strong performance in 2023, with sales growth of 14% and adjusted operating profit growth of 16%.
The company expects another year of meaningful growth in 2024, with sales growth projected to be between 5% and 7%, adjusted operating profit growth between 7% and 10%, and adjusted EPS growth between 6% and 9%.
GSK has upgraded its longer-term outlook, now expecting sales to grow more than 7% on a CAGR basis from 2021 to 2026. They also anticipate delivering over £38 billion in sales by 2031, an increase of £5 billion compared to their previous estimate.
Exclusive for Stockcircle Pro members
Sign up
$30.23
23% downside
Current Fair Value
23% downsideOvervalued by 23% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $84.56 Billion |
|---|---|
| Enterprise Value | $100.91 Billion |
| Dividend Yield | $1.4449 (3.54%) |
| Earnings per Share | $3.05 |
| Beta | 0.35 |
| Outstanding Shares | 2,072,439,973 |
| Avg 30 Day Volume | 2,620,640 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 13.47 |
|---|---|
| PEG | -16.48 |
| Price to Sales | 2.18 |
| Price to Book Ratio | 4.91 |
| Enterprise Value to Revenue | 2.61 |
| Enterprise Value to EBIT | 11.15 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 1.35 |
Revenue Sources
No data
ESG Score
No data
About Glaxosmithkline plc
CEO: Emma Walmsley